Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.46 |
| ▸ | P2RY10 | O00398 | 6/20 | 0.39 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.39 |
| ▸ | GPR174 | Q9BXC1 | 2/20 | 0.39 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.37 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.37 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6372215 | 1.00 | PLA2G2C (0.46) | PLA2G2CP2RY10GPR34GPR174PLA2G2D | |
| SCHEMBL8504216 | 0.93 | P2RY10 (0.45) | P2RY10GPR34GPR174LPAR1LPAR3 | |
| SCHEMBL6334072 | 0.88 | PLA2G2C (0.35) | PLA2G2CP2RY10GPR174 | |
| SCHEMBL9951880 | 0.86 | PLA2G2C (0.45) | PLA2G2CP2RY10GPR34GPR174PLA2G2D | |
| SCHEMBL9951445 | 0.86 | PLA2G2C (0.45) | PLA2G2CP2RY10GPR34GPR174PLA2G2D | |
| SCHEMBL4737508 | 0.86 | PLA2G2C (0.45) | PLA2G2CP2RY10GPR34GPR174PLA2G2D | |
| SCHEMBL27092071 | 0.84 | KDM4E (0.48) | P2RY10GPR34GPR174LPAR6LPAR1 | |
| Monoethanolamine SCHEMBL27656115 | 0.84 | PTPN1 (0.46) | LPAR6LPAR1LPAR4LPAR5LPAR2 | |
| SCHEMBL18797278 | 0.83 | PLA2G2C (0.35) | PLA2G2CP2RY10GPR34GPR174LPAR6 | |
| SCHEMBL2329616 | 0.83 | P2RY10 (0.42) | P2RY10GPR34GPR174 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023240156-A9 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES, AND METHODS OF SYNTHESIS AND USE THEREOF | TIDAL THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | claimed |
| US-20200297874-A1 | METHOD AND DEVICE FOR PRODUCING OPTIMIZED LIPID-BASED MICRO/NANO-BUBBLES | TRUST BIO SONICS INC (TW) | 2020-09-24 | — | — | US | claimed |
| US-20170360933-A1 | NUCLEIC ACID, MEDICAL NANOPARTICLE, AND PHARMACEUTICAL COMPOSITION THEREOF | CHUNG YUAN CHRISTIAN UNIVERSITY (TW) | 2017-12-21 | — | — | US | claimed |
| WO-2023240156-A9 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES, AND METHODS OF SYNTHESIS AND USE THEREOF | TIDAL THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20230295628-A1 | NUCLEIC ACID COMPLEX | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230277457-A1 | METHODS OF PREPARING LIPID NANOPARTICLES | ARES CAPITAL CORPORATION, AS AGENT | 2023-09-07 | — | — | US | disclosed |
| US-20230263905-A1 | SONOSENSITIVE LIPOSOME AND METHOD FOR PREPARING SAME | IMGT CO, LTD. (KR) | 2023-08-24 | — | — | US | disclosed |
| US-20230173104-A1 | LNP COMPOSITIONS COMPRISING AN MRNA THERAPEUTIC AND AN EFFECTOR MOLECULE | ARES CAPITAL CORPORATION, AS AGENT | 2023-06-08 | — | — | US | disclosed |
| US-11654109-B2 | Cavitation seed for drug delivery, and drug delivery method using same | PACIFIC SYSTEM CO., LTD. (KR) | 2023-05-23 | — | — | US | disclosed |
| US-11648260-B2 | Vesicles comprising a PTEN inhibitor and uses of same | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LIMITTED (IL) | 2023-05-16 | — | — | US | disclosed |
| US-20230126953-A1 | IONIZABLE CATIONIC LIPIDS | AKAGERA MEDICINES, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20190022019-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | MODERNATX INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-20180289838-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | ARES CAPITAL CORPORATION, AS AGENT | 2018-10-11 | — | — | US | disclosed |
| US-20180271795-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | ARES CAPITAL CORPORATION, AS AGENT | 2018-09-27 | — | — | US | disclosed |
| US-20180066256-A1 | RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Neuromuscular Disorders | BIOMARIN TECH BV (NL) | 2018-03-08 | — | — | US | disclosed |
| US-9861707-B2 | Treating bladder tumor cells using fibronectin attachment protein as a target | PURDUE RESEARCH FOUNDATION (US) | 2018-01-09 | — | — | US | disclosed |
| US-9744130-B2 | Cationic dry powders | PULMATRIX OPERATING COMPANY, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170095568-A1 | TREATING BLADDER TUMOR CELLS USING FIBRONECTIN ATTACHMENT PROTEIN AS A TARGET | PURDUE RESEARCH FOUNDATION | 2017-04-06 | — | — | US | disclosed |
| US-20170020813-A1 | CATIONIC DRY POWDERS | PULMATRIX OPERATING COMPANY, INC. (US) | 2017-01-26 | — | — | US | disclosed |
| US-20130156851-A1 | LIPOMACROCYCLES AND USES THEREOF | AGAVE PHARMA, INCORPORATED | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173104-A1 | LNP COMPOSITIONS COMPRISING AN MRNA THERAPEUTIC AND AN EFFECTOR MOLECULE | SNRPE, SNRPB2, SNRPF | PLA2G2C 720/4885P2RY10 4095/4885GPR34 4187/4885 |
| US-20230263905-A1 | SONOSENSITIVE LIPOSOME AND METHOD FOR PREPARING SAME | SON, CLPTM1L, SMPD1 | PLA2G2C 1078/4885P2RY10 3044/4885GPR34 3478/4885 |
| US-20170020813-A1 | CATIONIC DRY POWDERS | SLC30A5, SLC26A3, EXOSC9 | PLA2G2C 106/4885P2RY10 405/4885GPR34 2100/4885 |
| US-20180289838-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | POLM, EMG1, MCM6 | PLA2G2C 2780/4885P2RY10 4468/4885GPR34 4631/4885 |
| US-20230295628-A1 | NUCLEIC ACID COMPLEX | POLRMT, SNRPE, FABP7 | PLA2G2C 882/4885P2RY10 4084/4885GPR34 1999/4885 |
| US-20130156851-A1 | LIPOMACROCYCLES AND USES THEREOF | LIPC, LIPA, LIPE | PLA2G2C 462/4885P2RY10 3713/4885GPR34 742/4885 |
| US-20230126953-A1 | IONIZABLE CATIONIC LIPIDS | PHOSPHO1, LIPA, ABHD16A | PLA2G2C 59/4885P2RY10 3003/4885GPR34 3406/4885 |
| US-20230277457-A1 | METHODS OF PREPARING LIPID NANOPARTICLES | PLTP, LIPA, CETP | PLA2G2C 160/4885P2RY10 2906/4885GPR34 4832/4885 |
| US-20190022019-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | POLM, EMG1, MCM6 | PLA2G2C 2780/4885P2RY10 4468/4885GPR34 4631/4885 |
| US-20180271795-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | POLM, EMG1, MCM6 | PLA2G2C 2780/4885P2RY10 4468/4885GPR34 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.